October 8, 2024

Johnson & Johnson discontinues Phase III study of treatment for bladder cancer – Clinical Trials Arena

October 8, 2024

J&J’s TAR-200 Misses On Aim To Disrupt Muscle-Invasive Bladder Cancer – Scrip

October 8, 2024

J&J stops phase 3 trial of $5B bladder cancer prospect after interim review flop – Fierce Biotech

October 7, 2024

J&J discontinues late-stage study for bladder cancer drug – Reuters

October 6, 2024

Next-gen personalised radiotherapy could cure more bladder cancers and cut side effects – Cancer Research UK News